玻璃体内注射康柏西普对糖尿病黄斑水肿患者和继发于视网膜静脉阻塞的黄斑水肿患者的疗效差异  

Different efficacies of intravitreal injection of conbercept for diabetic macular edema and macular edema secondary to retinal vein obstruction

作　　者：朱婷婷 黄丹 张春元 孙瑞竹 刘振兴 顾喆瑶 马戈 奚婷 ZHU Tingting;HUANG Dan;ZHANG Chunyuan;SUN Ruizhu;LIU Zhenxing;GU Zheyao;MA Ge;XI Ting(Department of Ophthalmology,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School of Nanjing Medical Univercity,Suzhou 215008,Jiangsu Province,China)

机构地区：[1]南京医科大学姑苏学院,苏州市立医院,南京医科大学附属苏州医院眼科,江苏省苏州市215008

出　　处：《眼科新进展》2023年第1期53-56,共4页Recent Advances in Ophthalmology

基　　金：南京医科大学科技发展基金项目(编号:NMUB20210275)。

摘　　要：目的探讨玻璃体内注射康柏西普对糖尿病黄斑水肿(DME)患者和继发于视网膜静脉阻塞(RVO)的黄斑水肿患者的疗效差异。方法回顾性研究。选取2019年8月至2021年12月在苏州市立医院北区眼科行玻璃体内注射康柏西普治疗的DME患者44例63眼记为DME组,另选取采用同样方法进行治疗的继发于RVO的黄斑水肿患者40例40眼记为RVO组。采用国际标准视力表(小数)检查并记录患者最佳矫正视力(BCVA),采用德国海德堡公司OCT仪进行OCT检查,自动测量患者黄斑中心凹1 mm视网膜厚度并以此作为黄斑中心视网膜厚度(CMT)。所有患者玻璃体内均一次性注射0.05 mL康柏西普(成都康弘生物科技有限公司)。对比分析DME组和RVO组患眼基线特征及康柏西普治疗后7 d疗效差异。结果DME组患眼基线CMT为(484.94±152.89)μm,RVO组为(582.33±241.57)μm,RVO组基线CMT高于DME组,差异有统计学意义(P<0.05)。DME组患眼基线BCVA为0.31±0.20,RVO组为0.29±0.23,差异无统计学意义(P>0.05)。注射后7 d,DME组患眼CMT为(333.40±88.08)μm,较基线CMT改变量为(-151.54±118.24)μm,注射前后差异有统计学意义(t=10.173,P<0.01);注射后7 d,DME组患眼BCVA为0.59±0.23,较基线BCVA改变量为0.28±0.18,注射前后差异有统计学意义(t=-12.609,P<0.01)。注射后7 d,RVO组患眼CMT为(306.03±82.64)μm,较基线CMT改变量为(-276.30±214.88)μm,注射前后差异有统计学意义(t=8.132,P<0.01);注射后7 d,RVO组患眼BCVA为0.74±0.27,较基线BCVA改变量为0.45±0.21,注射前后差异有统计学意义(t=-13.258,P<0.01)。注射后7 d,RVO组患眼CMT减少量和BCVA提高量均高于DME组,差异均有统计学意义(均为P<0.05)。结论玻璃体内注射康柏西普治疗DME和继发于RVO的黄斑水肿在患者水肿消退及视力提高方面疗效均显著,继发于RVO的黄斑水肿患者经康柏西普治疗后疗效较DME患者更好。Objective To compare the different efficacies of intravitreal injection of conbercept(IVC)on patients with diabetic macular edema(DME)and patients with macular edema(ME)secondary to retinal vein obstruction(RVO).Methods In this retrospective study,patients who were treated with IVC from August 2019 to December 2021 in the Ophthalmology Department of Suzhou Municipal Hospital North Campus were included,among which 44 patients(63 eyes)with DME were divided into the DME group,and 40 patients(40 eyes)with ME secondary to RVO were divided into the RVO group.The international standard visual acuity chart(decimal)was used to check and record the best corrected visual acuity(BCVA)of the patients.The optical coherence tomography(OCT)instrument of Heidelberg Instruments was used to automatically measure the average retinal thickness of the macular fovea in the central 1 mm area as the central macular thickness(CMT).Conbercept(Chengdu Kanghong Biotechnology Co.,Ltd.)was administered intravitreally to all patients at a dose of 0.05 mL.The baseline characteristics and IVC efficacies in the DME group and RVO group were compared.Results The baseline CMT was(484.94±152.89)μm in the DME group and(582.33±241.57)μm in the RVO group,and the baseline CMT in the RVO group was significantly higher than that in the DME group(P<0.05).The baseline BCVA in the DME group was 0.31±0.20,and that in the RVO group was 0.29±0.23,with no statistically significant difference(P>0.05).At 7 d after the injection,the CMT in the DME group was(333.40±88.08)μm,changing by(-151.54±118.24)μm,with a statistically significant difference(t=10.173,P<0.01);the BCVA in the DME group was 0.59±0.23,changing by 0.28±0.18,with a statistically significant difference(t=-12.609,P<0.01).At 7d after the injection,the CMT in the RVO group was(306.03±82.64)μm,changing by(-276.30±214.88)μm,with a statistically significant difference(t=8.132,P<0.01);the BCVA was 0.74±0.27,changing by 0.45±0.21,with a statistically significant difference(t=-13.258,P<0.01).Th

关 键 词：血管内皮生长因子 糖尿病视网膜病变 视网膜静脉阻塞 康柏西普 黄斑水肿 

分 类 号：R774.5[医药卫生—眼科]